WinstonWınston
Back
Eckert & Ziegler SE logo

Eckert & Ziegler SE

EUZ.DE
73
Medical - Specialties · Healthcare
Also trades as: 0NZY.L
Price
€13.65
+0.17 (+1.26%)
Market Cap
€854.2M
Exchange
Frankfurt Stock Exchange
Winston Score
73
Winston is happy
A high-quality business with solid fundamentals.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Strong
Growth
Strong
Cash Flow
Strong
Stability
Exceptional
Valuation
Strong
Dividends
Weak

Winston Score History

The full picture

Eckert & Ziegler is a German company that makes radioactive materials used in medicine and industry. Its main products are radioisotopes — tiny amounts of radioactive substances used to treat cancer, diagnose diseases, and calibrate scientific equipment. Its customers include hospitals, cancer treatment centers, pharmaceutical companies, and research labs around the world.

The company earns money by producing and selling these radioactive materials, along with related devices and services. It operates primarily in Europe and North America, with a growing presence in other markets, and generates roughly €250–300 million in annual revenue. Its moat comes from the highly regulated nature of radioactive material production — getting government licenses to handle and ship these substances takes years, which keeps most competitors out. The key growth driver is the fast-expanding field of radioligand therapy, a cancer treatment method that uses targeted radioactive molecules, where Eckert & Ziegler is positioned as a supplier of critical isotope ingredients.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-5.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+103.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

€0/ year

Declining (-100% vs prior year)

0.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

35.7%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€128M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Eckert & Ziegler SE's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.9% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 62.3M (2021) → 62.8M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
48.1%
Healthy — 48.1% gross margin
Profit after running costs
Operating Margin
22.7%
Excellent — 22.7% operating margin
Return on the money invested
ROCE
26.9%
Exceptional — 26.9% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+4.4%
Slow sales growth (+4.4% YoY)
Profit growth
EPS YoY
+63.3%
Earnings growing fast (+63.3% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
104%
Turns 104% of profit into real cash
Spare cash per sale
FCF Margin
8.3%
Modest free cash flow (8.3%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.04
Conservative — low debt load (0.04)
Covers its interest
Interest Cover
72.04x
Comfortably covers interest (72.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
17.1x
Fair value — P/E 17.1

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
+3.2
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (17.1 → 13.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
1.61%
Small dividend — 1.61% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
-67.0%
Dividend cut (-67.0% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial